Euroimmun US Incorporated

Euroimmun US Incorporated, a wholly owned subsidiary of Revvity Inc. (formerly PerkinElmer), is a medical diagnostics company headquartered in Mountain Lakes, New Jersey, that specializes in immunodiagnostic testing solutions and laboratory equipment. The company serves the federal government as a prime contractor providing specialized diagnostic reagents, test kits, and medical supplies to support healthcare and research initiatives across multiple federal agencies. With a registration in SAM.gov dating back to June 2006, Euroimmun US Incorporated maintains an active federal contracting presence and has established itself as a reliable supplier of proprietary diagnostic products to the Department of Veterans Affairs, Department of the Army, and the Department of Health and Human Services.

Euroimmun US Incorporated has demonstrated extensive federal contracting experience through a diverse portfolio of purchase orders and Blanket Purchase Agreement calls. The company has primarily supplied T-SPOT TB reagents and test kits to the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, with delivery orders ranging from $23,764.50 to $69,125.80 for tuberculosis diagnostic screening products performed at its Mountain Lakes, New Jersey facility. Beyond tuberculosis diagnostics, Euroimmun has provided maintenance and repair services for specialized microscope equipment, including preventative and corrective maintenance for EUROIMMUN IF Sprinter and EUROPATTERN 1.5 microscopes at the Edward Hines Jr. VA Hospital under a $109,252.50 purchase order awarded by Veterans Integrated Service Network 12. The company also supplied COVID-19 diagnostic products during the pandemic response, delivering anti-SARS-CoV-2 IGG ELISA kits to the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases with contract values ranging from $12,475 to $33,175. Additionally, Euroimmun provided a Rat/Mouse PINP EIA/Mouse TRAP Assay antibody testing product to the National Institute of Dental and Craniofacial Research valued at $43,289.75. All of these awards were made without set-aside designations through open or sole-source competitive procedures, reflecting the proprietary nature of many Euroimmun products and the company's established relationships with federal medical procurement offices. The company also served as a subcontractor to ICF Macro Inc. in support of the 2023 Zimbabwe Demographic and Health Survey disbursing services contract.

Euroimmun US Incorporated currently holds two significant Indefinite Delivery Contracts with federal agencies. The Department of the Army Medical Command awarded a single-award Indefinite Delivery Contract valued at $2.4 million on January 4, 2024, with an ultimate completion date of January 3, 2029, for the supply of immunodiagnostic systems reagents and supplies to support the Army's medical diagnostic and testing capabilities. Under this indefinite delivery vehicle, a delivery order for medical supplies valued at $20,957 was issued on April 15, 2024, for performance at the contractor's Mountain Lakes location. The second IDV is a Blanket Purchase Agreement with the Department of Veterans Affairs Veterans Integrated Service Network 2, awarded on October 1, 2021, with a ceiling value of $1,128,588.50 and ultimate completion date of September 30, 2026, for T-SPOT TB reagents and related services supporting tuberculosis screening efforts in VA New England healthcare facilities. Under this BPA vehicle, Euroimmun has received multiple annual call orders with firm fixed-price structures and values ranging from $23,764.50 to approximately $128,337.80, including a $53,847 purchase order from Veterans Integrated Service Network 16 awarded October 27, 2025, a $50,031.40 BPA call for Option Year 3 awarded October 1, 2025, and a $54,395.60 delivery order awarded October 1, 2024. Both indefinite delivery contracts were awarded without set-aside designations and represent the company's core federal business supporting specialized medical diagnostic capabilities across the federal healthcare system.